课题基金 / 基金详情

NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER

NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER
干预炎症性疾病和癌症的新策略
批准号:
10077119
负责人:
Rongfu Wang
金额:
$31.35万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2023-05-31

项目摘要

项目成果

Rongfu Wang的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 结直肠癌(CRC)是美国第三大癌症死亡原因,是一种具有挑战性的疾病 涉及免疫细胞、细胞因子介导的途径和肠道微生物区系之间的复杂相互作用-导致 炎症、上皮组织屏障破坏、急性结肠炎和结直肠癌的发展。因此,机械论 迫切需要研究以澄清这些关键变量的相互作用和后果,使 确定治疗干预的新靶点。在我们之前的奖项资助的研究过程中 (R01CA101795)中,我们发现Tak1(转化生长因子-β激活的蛋白激酶1)是一种负向调节因子,即核因子-κB信号转导通路。 在中性粒细胞中发现其在髓系(Tak1ΔM/ΔM)中的特异性缺失导致增加 促炎细胞因子(IL-1β、IL-6和肿瘤坏死因子-α)和对内毒素诱导的感染性休克的更高敏感性。 出乎意料的是,Tak1ΔM/ΔM小鼠对化学诱导的急性结肠炎和结直肠癌完全耐受 发展。这种表型与Th17和ILC3细胞在肠道中的显著聚集有关。 固有层和肠道微生物区系组成的变化。进一步的研究显示出显著的抑制 结肠上皮细胞中趋化因子的表达和免疫细胞向结肠组织的运输。这些耐人寻味 新的发现导致我们假设特定的肠道微生物区系,Th17和ILC3细胞及其细胞因子(IL-17 和IL-22)在调节对结肠炎和炎症相关结直肠癌的抵抗力方面发挥关键作用 结肠上皮细胞抑制趋化因子的表达。这一假说的关键预测将得到检验。 在三个具体的研究目标中,都依赖于Tak1ΔM/ΔM模型抑制结肠炎和结直肠癌的发生。 目标1旨在鉴定有助于Th17和ILC3细胞积聚的特定微生物群 从而抵抗实验性结肠炎和结直肠癌。目标2将定义Th17和ILC3细胞的功能 (及其细胞因子)在促进对化学诱导的结肠炎和结直肠癌的抵抗力方面,而目标3将测试 假设Th17/ILC3来源的细胞因子抑制结肠上皮细胞趋化因子的表达,因此 阻断随后免疫细胞对上皮层的渗透,最终诱导癌变 冒号的变化。 在成功完成这项工作后,我们预计将对 推动溃疡性结肠炎和结直肠癌发展的炎症过程,因此具有潜在的 这一网络中的漏洞可能成为预防或治疗这些疾病的目标。
英文摘要
PROJECT SUMMARY Colorectal cancer (CRC), the third leading cause of cancer deaths in the United States, is a challenging disease involving complex interplay among immune cells, cytokine-mediated pathways and gut microbiota – leading to inflammation, disruption of the epithelial tissue barrier, acute colitis and CRC development. Thus, mechanistic studies are urgently needed to clarify the interactions and consequences of these key variables, enabling the identification of novel targets for therapeutic intervention. In the course of studies funded by our previous award (R01 CA101795), we identified TAK1 (TGF-beta-activated kinase 1) as a negative regulator of NF-κB signaling in neutrophils and found that its specific deletion in the myeloid lineage (Tak1ΔM/ΔM) leads to increased proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and greater sensitivity to LPS-induced septic shock. Unexpectedly, Tak1ΔM/ΔM mice were completely resistant to chemically induced acute colitis and CRC development. This phenotype was associated with a marked accumulation of Th17 and ILC3 cells in the intestinal lamina propria and alterations of the gut microbiota composition. Further studies showed significant suppression of chemokine expression in colon epithelial cells and of immune cell trafficking into colon tissues. These intriguing new findings led us to hypothesize that specific gut microbiota, Th17 and ILC3 cells and their cytokines (IL-17 and IL-22) play critical roles in regulating resistance to colitis and inflammation-related CRC through the suppression of chemokine expression by colon epithelial cells. Key predictions of this hypothesis will be tested in three specific research aims, all relying on the Tak1ΔM/ΔM model of suppressed colitis and CRC tumorigenesis. Aim 1 seeks to identify specific strains of microbiota that contribute to the accumulation of Th17 and ILC3 cells and thus to resistance to experimental colitis and CRC. Aim 2 will define the functions of Th17 and ILC3 cells (and of their cytokines) in promoting resistance to chemically induced colitis and CRC, while Aim 3 will test the hypothesis that Th17/ILC3-derived cytokines inhibit the expression of chemokines by colon epithelial cells, thus blocking subsequent immune cell infiltration of the epithelial layer and ultimately the induction of malignant changes in the colon. Upon successful completion of this work, we expect to have a much-improved understanding of the inflammatory processes that drive the development of ulcerative colitis and CRC, and thus of potential vulnerabilities in this network that could be targeted for the prevention or treatment of these disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD4+ T cells and neoantigens in melanoma immunotherapy.
CD4+ T cells and neoantigens in melanoma immunotherapy.
Transport of Effector T cells and Nano-DC vaccine in Breast Cancer
Antigen specificity, suppressive mechanism & regulation of CD4+ regulatory T cell
  • 批准号:
    7653641
  • 项目类别:
  • 资助金额:
    $25.85万
  • 财政年份:
    2006
  • 负责人:
    Rongfu Wang
  • 依托单位:
海外基金